Yumanity Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 08/12/21
Yumanity Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 05/13/21
Yumanity Therapeutics to Present at the 2021 RBC Capital Markets Global Healthcare ConferenceGlobeNewsWire • 05/12/21
Yumanity Therapeutics to Present at the 2021 B. Riley Securities' Neuroscience ConferenceGlobeNewsWire • 04/29/21
Yumanity Therapeutics' YTX-7739 Achieved Target Engagement at Doses That Were Generally Well Tolerated in a Phase 1a Multiple Ascending Dose Study in Healthy VolunteersGlobeNewsWire • 04/22/21
Yumanity Therapeutics Appoints Neuroscience Drug Development Veteran, Ajay Verma, M.D., Ph.D., Executive Vice President, Head of Research & DevelopmentGlobeNewsWire • 04/13/21
Yumanity Therapeutics Announces Study Demonstrating In Vivo Efficacy of YTX-7739 in a Glioblastoma Multiforme (GBM) Mouse ModelGlobeNewsWire • 04/06/21
Yumanity Therapeutics Reports Full Year 2020 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 03/31/21
Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences ConferenceGlobeNewsWire • 03/02/21
Yumanity Therapeutics Sees Lead Candidate Interim Data From Early-Stage Parkinson's Study By Mid-2021Benzinga • 02/10/21
Yumanity Therapeutics Provides Update on Its Lead Parkinson's Disease Clinical Program, YTX-7739GlobeNewsWire • 02/10/21
Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect ConferenceGlobeNewsWire • 01/06/21
Yumanity Therapeutics Completes Reverse Merger with Proteostasis TherapeuticsGlobeNewsWire • 12/23/20